ERBB2 and triple-negative breast carcinoma: In the present study, we showed a novel co-targeting strategy by combined inhibition of BRD4-RAC1 signaling pathways in different molecular subtypes of breast cancer including luminal-A, HER-2 positive and triple-negative breast cancer (TNBC).